Live price temporarily unavailable.
Cue Biopharma (CUE) is a Health Care company. Latest news and coverage below.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | $1.14M | $3.46M | $3.15M | $14.9M | $1.25M | $5.49M | $9.29M | $27.5M |
| Growth (year over year) | — | — | +202.7% | −8.8% | +373.7% | −91.7% | +341.0% | +69.2% | +195.7% |
| Operating income | −$23.2M | −$38.7M | −$36.8M | −$45.0M | −$43.7M | −$53.2M | −$52.1M | −$41.5M | −$26.6M |
| Operating margin | — | −3386.7% | −1063.2% | −1428.0% | −292.6% | −4275.1% | −949.9% | −446.9% | −96.7% |
| Net income | −$23.2M | −$39.0M | −$36.7M | −$44.8M | −$44.2M | −$53.0M | −$50.7M | −$40.7M | −$26.6M |
| Net margin | — | −3411.5% | −1061.2% | −1419.8% | −295.6% | −4257.8% | −924.1% | −438.0% | −96.9% |
| EPS (diluted) | −$1944.00 | −$1746.00 | −$1494.00 | −$1404.00 | −$42.30 | −$44.70 | −$33.30 | −$21.60 | −$8.40 |
| Balance sheet | |||||||||
| Cash and equivalents | $63.5M | $20.8M | $44.3M | $74.9M | $64.4M | $51.6M | $48.5M | $22.5M | $27.1M |
| Total assets | $67.0M | $45.4M | $71.6M | $99.5M | $83.4M | $91.3M | $61.5M | $32.2M | $42.2M |
| Total liabilities | $5.35M | $11.4M | $17.0M | $20.6M | $17.9M | $25.6M | $24.4M | $14.7M | $15.8M |
| Long-term debt | — | — | — | — | $0 | $8.04M | $4.20M | $0 | — |
| Shareholders' equity | $61.6M | $34.0M | $54.6M | $78.9M | $65.5M | $65.7M | $37.1M | $17.5M | $26.4M |
| Cash flow | |||||||||
| Operating cash flow | −$12.1M | −$26.4M | −$30.8M | −$32.5M | −$38.8M | −$41.8M | −$40.0M | −$36.3M | −$21.7M |
| Capital expenditure | $1.03M | $1.85M | $46.4K | $595.3K | $913.0K | $171.0K | $0 | $66.0K | $177.0K |
| Free cash flow | −$13.2M | −$28.3M | −$30.8M | −$33.1M | −$39.8M | −$42.0M | −$40.0M | −$36.4M | −$21.9M |
| Share buybacks | — | — | $91.0K | $271.1K | $750.1K | $200.0K | $0 | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.34M | $1.58M | $421.0K | $2.95M | $2.15M | — | $5.69M | $7.88M |
| Growth (year over year) | +58.9% | −13.5% | −75.5% | +11.1% | −35.6% | — | +1250.6% | +166.7% |
| Operating income | −$8.81M | −$9.63M | −$12.3M | −$8.63M | −$7.59M | — | −$5.35M | −$87.7M |
| Operating margin | −264.2% | −611.3% | −2921.4% | −292.3% | −353.4% | — | −94.1% | −1113.3% |
| Net income | −$8.66M | −$9.50M | −$12.3M | −$8.48M | −$7.45M | — | −$5.18M | −$153.1M |
| Net margin | −259.6% | −602.5% | −2911.4% | −287.1% | −346.6% | — | −91.1% | −1943.2% |
| EPS (diluted) | −$5.10 | −$3.00 | −$148.50 | −$2.67 | −$2.10 | — | −$32.40 | −$24.14 |
| Balance sheet | ||||||||
| Cash and equivalents | $32.4M | $22.5M | $13.1M | $27.5M | $11.7M | $27.1M | $16.4M | $17.4M |
| Total assets | $44.8M | $32.2M | $22.3M | $40.7M | $31.6M | $42.2M | $30.9M | $30.7M |
| Total liabilities | $19.4M | $14.7M | $15.7M | $22.5M | $18.4M | $15.8M | $9.27M | $28.4M |
| Long-term debt | $1.33M | $0 | — | — | — | — | — | — |
| Shareholders' equity | $25.4M | $17.5M | $6.58M | $18.2M | $13.2M | $26.4M | $21.6M | $2.31M |
| Cash flow | ||||||||
| Operating cash flow | −$7.53M | −$9.03M | −$8.17M | −$3.42M | −$9.02M | — | −$10.9M | −$29.0M |
| Capital expenditure | −$1.00K | $2.00K | $150.0K | $27.0K | $0 | — | $121.0K | $0 |
| Free cash flow | −$7.53M | −$9.03M | −$8.32M | −$3.44M | −$9.02M | — | −$11.1M | −$29.0M |
From Cue Biopharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Cue Biopharma in our feed yet.